INVOKAMET 50 MG
CANAGLIFLOZIN : 50 MG METFORMIN HYDROCHLORIDE : 850 MG · DIN 02455412 · JANSSEN INC
Health Canada status: CANCELLED POST MARKET
What is INVOKAMET?
INVOKAMET 50 MG contains CANAGLIFLOZIN : 50 MG METFORMIN HYDROCHLORIDE : 850 MG. It is listed in the Health Canada Drug Product Database under DIN 02455412, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 06-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02455412 |
|---|---|
| Brand name | INVOKAMET |
| Generic / active ingredient | CANAGLIFLOZIN : 50 MG METFORMIN HYDROCHLORIDE : 850 MG |
| Manufacturer | JANSSEN INC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BD16 METFORMIN AND CANAGLIFLOZIN |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 06-Sep-2022 |
What can be used instead?
Other Canadian products sharing ATC code A10BD16 METFORMIN AND CANAGLIFLOZIN. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| INVOKAMET | 1000 MG | TABLET | JANSSEN INC | MARKETED | DIN 02455455 |
| INVOKAMET | 50 MG | TABLET | JANSSEN INC | MARKETED | DIN 02455420 |
| INVOKAMET | 50 MG | TABLET | JANSSEN INC | MARKETED | DIN 02455404 |
| INVOKAMET | 500 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | DIN 02455439 |
| INVOKAMET | 850 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | DIN 02455447 |
| INVOKAMET XR | 1000 MG | TABLET (EXTENDED-RELEASE) | JANSSEN INC | CANCELLED PRE MARKET | DIN 02477408 |
| INVOKAMET XR | 500 MG | TABLET (EXTENDED-RELEASE) | JANSSEN INC | CANCELLED PRE MARKET | DIN 02477394 |
| INVOKAMET XR | 500 MG | TABLET (EXTENDED-RELEASE) | JANSSEN INC | CANCELLED PRE MARKET | DIN 02477416 |
| INVOKAMET XR | Strength | Tablet (Extended-Release) | JANSSEN INC 19 Green Belt Drive Toronto Ontario Canada M3C 1L9 | CANCELLED PRE MARKET | DIN 02477424 |
Who else supplies METFORMIN AND CANAGLIFLOZIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METFORMIN AND CANAGLIFLOZIN appears in 1377 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.